Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Xiaoxiang Chen
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04556071CT.gov Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer | — | Unknown | — | — | — |
NCT02734004CT.gov A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | — | Active Not Recruiting | — | — | — |
NCT02331251CT.gov Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | Xiaoxiang Chen | P3 | BB · 70 |
| Adriamycin | Innovent Biologics (Suzhou) Co. Ltd. | P3 | BB |
| Carboplatin | Fujian Cancer Hospital | P3 | BB |
| Olaparib | Xiaoxiang Chen | P2 | BB |
| ibi354 | Innovent Biologics (Suzhou) Co. Ltd. | P3 | B |
| Pembrolizumab | Sheba Medical Center | P2 | B |
| Dexasone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P2 | B |
| Temsirolimus | AGO Study Group | P2 | B |
| Trabectedin | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P2 | B |
+16 more in the Ovarian Disorder cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Irinotecan in Ovarian Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-ovarian-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →